Following the specification into the financial account

I review slow-moving inventory with the specification and likely customer use attached to the financial record. Age is a useful signal, but it does not answer whether a lot remains saleable, can be converted economically or has lost its intended application. Product, quality and commercial colleagues provide that evidence. Finance then assesses the carrying value with the relevant accounting advice and records the basis for later review. I do not treat a write-down as cash released or assume that material becomes valuable because another site could theoretically process it. Conversion has a cost, a technical decision and a credible demand requirement. The practical question is what the company can reasonably do with the specific stock it holds. That account should inform future purchasing and production choices as well as the number reported at the closing date.

A customer's interest in a specialised fabric is not the same as a commitment to take every metre produced for it. I work with sales and legal colleagues to understand the agreed specification, release schedule, minimum quantities and consequences of a change. Finance estimates the exposure created by dedicated yarn, finishing work and inventory that has few alternative uses. We then consider deposits, staged purchases or different commercial terms as part of the negotiation. A deposit may reduce the initial cash requirement without covering the entire risk, so I show what remains. I also ask the technical team which commitments cannot sensibly be split into smaller stages. The objective is to support a useful customer relationship with terms both parties understand, rather than accept a narrow custom product on assumptions that only become visible when the customer changes its plan.

A standard cost can make two months appear comparable even when the plant has handled a different mixture of widths, finishes and run lengths. I work with the controller and operating team to identify which changes explain the result. Longer runs may improve a unit-cost measure while increasing inventory with limited demand. More changeovers may reflect customer requirements rather than poor scheduling. I want the financial review to retain those distinctions before it recommends a response. That does not remove the need for discipline or make every adverse movement unavoidable. It makes the proposed action more specific. A decision about order terms differs from a decision about process performance, and both differ from an accounting allocation. The plant manager should be able to recognise the operating reality in the financial explanation, even when we disagree about the next choice.

I ask which products and operating conditions support the benefit claimed for new equipment. A supplier demonstration or a limited trial may be encouraging without establishing the result across the full range. Engineering and quality colleagues define the technical evidence; finance compares the expenditure and transition costs against the benefits that evidence can support. I also examine training, product approvals and the cost of maintaining the existing process during introduction. If the case depends on a throughput level or rejection-rate improvement that has not been demonstrated, the board should see that dependency explicitly. A staged trial can be appropriate, but it has its own cost and may delay a useful investment. I want those trade-offs visible rather than assume either a full purchase or indefinite testing is inherently the more responsible choice.